| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Orthopaedic Surgery, Division of Endocrinology, The Milton S. Hershey Medical Center Pennsylvania State University Hershey, Pennsylvania 17033
Address all correspondence and requests for reprints to: James R. Buchanan, M.D., Division of Orthopaedic Surgery, The Milton S. Hershey Medical Center, P.O. Box 850, Hershey, Pennsylvania 17033.
To determine whether endogenous androgens influence bone density in young women, we studied 27 normal women and 19 women with androgen excess, as defined by increased serum bioavailable testosterone (bio T) concentrations. The women ranged from 21–48 yr of age. The 2 groups were comparable with respect to age, anthropomorphic measures, nutrition, gynecological history, and serum cortisol and estradiol levels. Trabecular (lumbar) and cortical (radial) bone density were quantitated by computerized tomography and single photon absorptiometry, respectively. Serum obtained during the follicular phase of the cycle was assayed for bio T, total T, dehydroepiandrosterone sulfate, androstenedione (Adione), and 3
-androstanediol glucuronide (3-Adiol-G).
Trabecular bone density was significantly higher in the androgen excess group [172 ± 7 (±SE) vs. 153 ± 5 mg/mL; P = 0.03]; controlling for serum Adione (but not for serum bio T, total T, dehydroepiandrosterone sulfate, or 3-androstanediol glucuronide, or 3-Adiol-G) abolished this difference. Similarly, serum Adione correlated more strongly than the other androgens with trabecular bone density (r = 0.31; P = 0.03). Average cortical bone density was not higher in the androgen excess group (0.740 ± 0.014 vs. 0.722 ± 0.008 g/cm2; P = 0.27). Among the 27 normal women, cortical density was correlated to serum bio T (r = 0.47; P = 0.01) and total T (r = 0.53; P = 0.004), but not to the other androgens.
We conclude that supraphysiological levels of endogenous androgens are associated with increased trabecular bone density in young women. Serum Adione appeared to be the best marker for the impact of androgen on trabecular density. Among normal women, cortical bone density was related to serum T
Received February 15, 1988.
This article has been cited by other articles:
 |
|
 |
|
  E. A. Ariazi, A. Leitao, T. I. Oprea, B. Chen, T. Louis, A. M. Bertucci, C. G.N. Sharma, S. D. Gill, H. R. Kim, H. A. Shupp, et al. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen Mol. Cancer Ther., November 1, 2007; 6(11): 2817 - 2827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Chien and P. E. Goss Aromatase Inhibitors and Bone Health in Women With Breast Cancer J. Clin. Oncol., November 20, 2006; 24(33): 5305 - 5312. [Full Text] [PDF]
|
|
|
|
 |
|
 L.M. Rivera-Woll, M. Papalia, S.R. Davis, and H.G. Burger Androgen insufficiency in women: diagnostic and therapeutic implications Hum. Reprod. Update, September 1, 2004; 10(5): 421 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Vanderschueren, L. Vandenput, S. Boonen, M. K. Lindberg, R. Bouillon, and C. Ohlsson Androgens and Bone Endocr. Rev., June 1, 2004; 25(3): 389 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Issa, D. Schnabel, M. Feix, L. Wolf, H.-E. Schaefer, D. W. Russell, and H.-U. Schweikert Human Osteoblast-Like Cells Express Predominantly Steroid 5{alpha}-Reductase Type 1 J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5401 - 5407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Compston Sex Steroids and Bone Physiol Rev, January 1, 2001; 81(1): 419 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Zborowski, J. A. Cauley, E. O. Talbott, D. S. Guzick, and S. J. Winters Bone Mineral Density, Androgens, and the Polycystic Ovary: The Complex and Controversial Issue of Androgenic Influence in Female Bone J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3496 - 3506. [Full Text]
|
|
|
|
|
|
R. Marcus, D. Leary, D. L. Schneider, E. Shane, M. Favus, and C. A. Quigley The Contribution of Testosterone to Skeletal Development and Maintenance: Lessons from the Androgen Insensitivity Syndrome J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1032 - 1037. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Gori, L. C. Hofbauer, C. A. Conover, and S. Khosla Effects of Androgens on the Insulin-Like Growth Factor System in an Androgen-Responsive Human Osteoblastic Cell Line Endocrinology, December 1, 1999; 140(12): 5579 - 5586. [Abstract] [Full Text]
|
|
|
|
|
|
C. Massafra, C. De Felice, D. P. Agnusdei, D. Gioia, and F. Bagnoli Androgens and Osteocalcin during the Menstrual Cycle J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 971 - 974. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. Pederson, M. Kremer, J. Judd, D. Pascoe, T. C. Spelsberg, B. L. Riggs, and M. J. Oursler Androgens regulate bone resorption activity of isolated osteoclasts in vitro PNAS, January 19, 1999; 96(2): 505 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Lea and A. M. Flanagan Physiological plasma levels of androgens reduce bone loss in the ovariectomized rat Am J Physiol Endocrinol Metab, February 1, 1998; 274(2): E328 - E335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Wiren, X. Zhang, C. Chang, E. Keenan, and E. S. Orwoll Transcriptional Up-Regulation of the Human Androgen Receptor by Androgen in Bone Cells Endocrinology, June 1, 1997; 138(6): 2291 - 2300. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
